Moderna Inc


Why Moderna Stock Is Still a Strong Buy Now

For months, biotech companies and government officials talked about eventually needing a coronavirus booster vaccine.

Now that the Delta variant accounts for 98.8% of new U.S. infections, the possibility of wheeling out a booster is more real.

Moderna stock (NASDAQ: MRNA) got a huge pop since rolling out its initial vaccines.

It's up 466%% year-over-year.

Now, investors hope another round of vaccine distributions may fuel the company's bottom line and translate to similar gains.

They could be right…



The One mRNA Vaccine Stock to Buy Today

Pfizer, BioNTech, and Moderna investors enjoyed massive gains from late 2020 to early 2021 as the "vaccine stocks" exploded in value as their product was authorized.

Here's the thing, though – the profits aren't finished.

One company is set to experience another round of big gains over the next year or more.

Michael A. Robinson has the ticker…



This Cheap Stock Opens up a $100 Billion Medical Market

Understandably, a lot of the world's medical and scientific firepower was focused on coronavirus vaccines this year.

But other advances in medicine have the potential to do even more for investors than the "vaccine stocks" did.

Shah's looking at a potential $100 billion medical market, and sizing up a $6 stock to play it…



How to Profit in a $29 Billion “New Biotech” Sector

Back in the late 1960s and early 1970s, psychedelics drugs like LSD were still legal and could be researched.

But in 1968 when the federal government criminalized them, a lot of promising research stopped.

Now the spotlight is back on these drugs and the success they’ve shown in clinical trials for treating a range of mental health conditions.

This is not only great news for people suffering from these conditions, but also for savvy investors who’ll get in on the ground floor of a market that could be worth more than $29 billion by the end of the decade.

Here’s Shah with all the details….



This COVID-19 Vaccine Stock Has More Upside Than Pfizer or Moderna

Developing effective vaccines against a deadly global pandemic is certainly bullish for a stock.

Indeed, Moderna and Pfizer shareholders have put away as much as 516% and 51% gains, respectively.

And when a lot of investors see this, they fear they’ve missed out.

Well, Michael’s here to assure you that you haven’t; not by a long shot.

And today, he’s got a vaccine stock you should put at the top of your “must-buy” list for the week ahead… .